Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-10-22 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
监事会关于第三届监事会第二十次会议相关事项的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding their review and opinions on matters related to the use and delay of certain raised funds projects. It references compliance with company law, stock exchange listing rules, and company articles of association. The document is relatively short (901 characters) and serves as an official opinion and announcement rather than a detailed financial report or presentation. It does not contain financial statements or detailed financial data, nor is it a transcript, audit, or management report. It is an announcement related to capital use and fundraising projects, specifically about changes and delays in the use of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-10-22 Chinese
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会工作细则' which translates to 'Board Audit Committee Working Rules'. It details the structure, responsibilities, meeting procedures, and decision-making processes of the audit committee within the board of directors. It is a governance-related document outlining internal rules and committee functions rather than a financial report, audit report, or announcement of voting results. There is no indication of financial data, audit opinions, or shareholder voting outcomes. The document is a formal governance framework issued by the board, fitting the category of Governance Information (CGR). The document length is 3462 characters, which is sufficient for a detailed governance report rather than a brief announcement. Therefore, the classification is Governance Information (CGR) with high confidence.
2023-10-22 Chinese
独立董事专门会议工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议工作制度' which translates to 'Independent Directors Special Meeting Working System'. It details the rules and procedures for independent directors' meetings, including meeting convening, voting, powers, and record-keeping. It references company laws and regulations but does not contain financial data, earnings, or audit results. It is a governance-related document outlining internal board procedures rather than a report or announcement of financial results or corporate actions. The document length is 2632 characters, which is relatively short and focused on governance rules. Therefore, the most appropriate classification is Governance Information (CGR).
2023-10-22 Chinese
关于召开2023年第二次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2023 second extraordinary general meeting of shareholders for Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and other logistical information. There is no actual voting result, financial data, or report content included. The document is an announcement about the meeting itself, not the meeting minutes or voting results. Therefore, it fits the category of a shareholder meeting notice rather than a voting results declaration or a full report. Given the options, this is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and does not fit other more specific categories like DVA (Declaration of Voting Results) or PSI (Proxy Solicitation). The document length is under 5,000 characters, consistent with an announcement rather than a full report.
2023-10-22 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 Third Quarter Report" of Jiangsu Deyuan Pharmaceutical Co., Ltd. It contains detailed financial data for the third quarter of 2023, including balance sheet items, income statement figures, cash flow data, explanations of significant changes, shareholder information, and details on corporate events such as stock incentive plans and share repurchases. The document explicitly states it is a quarterly report and includes comprehensive financial statements and management discussion. It is not a brief announcement or a certification letter but a full interim financial report covering a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-22 Chinese
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase and cancellation, including details on the number of shares repurchased, the impact on share capital, and subsequent corporate actions. It does not contain financial statements or detailed financial performance data. The content focuses on share buyback and capital structure changes. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2023-10-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.